11:16 AM EDT, 10/24/2024 (MT Newswires) -- Casi Pharmaceuticals ( CASI ) said Thursday that the Center for Drug Evaluation of China's National Medical Products Administration has approved the conduct of a phase 1/2 clinical trial of CID-103 in adults with chronic immune thrombocytopenia.

The China study is part of a global clinical trial approved by the US Food and Drug Administration in May, according to the company.

Casi said CID-103 is a monoclonal antibody that has shown "encouraging" preclinical efficacy and safety profile.

The company's shares were up more than 3% in recent trading.

Price: 5.69, Change: +0.20, Percent Change: +3.64